Gamma Biosciences is an innovator in life sciences focused on bioprocessing tools and technologies for the development and production of advanced therapies, including vaccines, biologics and cell and gene therapies. Our operating companies are Astrea Bioseparations (Cambridge, UK) and Univercells Technologies (Brussels, Belgium).

Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today.Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and bioengineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011.CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.

Instructor for AAP joint MS Biotechnology/MBA program

Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. The company is located in the I-270 "High technology Corridor" in Gaithersburg, Maryland. Trevigen-brand research products are marketed via the Internet, catalog, journal advertising, direct mail, and telemarketing. Distributor appointments have been made in North America, Europe, and the Pacific Rim. Trevigen also has in place supply agreements with major government and university medical research centers. The company is the recipient of several SBIR grants from the National Institutes of Health, concerning technology development for the analysis of DNA damage.